Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes

• Published in: Graefe's archive for clinical and experimental ophthalmology Vol. 260; no. 11; pp. 3489 - 3498
• Main Authors: Sugimoto, Masahiko, Handa, Chiharu, Hirano, Kazufumi, Sunaya, Toshiyuki, Kondo, Mineo
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2022; Springer Nature B.V
• Subjects: Acuity; Clinical medicine; Clinical trials; Diabetes; Diabetes mellitus; Diabetic retinopathy; Edema; Injection; Medicine; Medicine & Public Health; Ophthalmology; Patients; Retina; Retinal Disorders; Safety; Japan; Anti-vascular endothelial growth factor treatment; Real-world clinical practice; Intravitreal aflibercept; Diabetic macular edema
• ISSN: 0721-832X; 1435-702X
• DOI: 10.1007/s00417-022-05703-9

Purpose To report the safety and effectiveness of intravitreal aflibercept (IVT-AFL) for diabetic macular edema (DME) in the real-world clinical practice setting in Japan. Methods In this prospective, multicenter, observational, post-marketing surveillance, patients with DME newly receiving IVT-AFL were enrolled. During a 24-month follow-up, the primary outcome was the occurrence of safety events. Other pre-specified endpoints were effectiveness indicators, such as best-corrected visual acuity (BCVA), central retinal thickness, and injection frequency. Results In total, 646 patients administered at least one IVT-AFL injection were included in the safety analysis. During the follow-up period, adverse events occurred in 42 patients (6.50%), whereas adverse drug reactions occurred in 12 (1.86%). In the 12 patients who had adverse drug reactions, seven events occurred in seven patients within the first month of the most recent injection. In addition, 622 patients were included in the effectiveness analysis set. The number of injections over 24 months was 3.6 ± 3.0 (mean ± standard deviation [ SD ]). BCVA (logarithm of the minimum angle of resolution) was 0.437 ± 0.362 (mean ± SD) ( n  = 622) at baseline and 0.321 ± 0.348 ( n  = 177) after 24 months of treatment with IVT-AFL. Central retinal thickness was 440.8 ± 134.2 μm (mean ± SD) ( n  = 444) at baseline and 355.5 ± 126.4 μm ( n  = 140) at 24 months. Conclusion Routine administration of IVT-AFL for DME was not associated with new safety concerns, and BCVA outcomes were maintained over 24 months in the real-world setting. Nonetheless, patients in this real-world setting received fewer injections than those in clinical trials, suggesting that a margin for improvement exists in clinical practice. Trial registration ClinicalTrials.gov: NCT02425501.